dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Julia Cano, Antonio |
dc.contributor.author | Bonafonte Pardàs, Irene |
dc.contributor.author | Gomez Moruno, Antonio |
dc.contributor.author | Lopez Lasanta, Maria America |
dc.contributor.author | Lopez Corbeto, Mireia |
dc.contributor.author | Martinez Mateu, Sergio Hilario |
dc.contributor.author | Llados Segura, Jordi Francesc |
dc.contributor.author | Marsal Barril, Sara |
dc.date.accessioned | 2022-01-14T11:16:03Z |
dc.date.available | 2022-01-14T11:16:03Z |
dc.date.issued | 2021-06-01 |
dc.identifier.citation | Julià A, Bonafonte-Pardàs I, Gómez A, López-Lasanta M, López-Corbeto M, Martínez-Mateu SH, et al. Targeting of the CD80/86 proinflammatory axis as a therapeutic strategy to prevent severe COVID-19. Sci Rep. 2021 Jun 1;11:11462. |
dc.identifier.issn | 2045-2322 |
dc.identifier.uri | https://hdl.handle.net/11351/6803 |
dc.description | Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Malalties inflamatòries; Identificació de l'objectiu; Infecció viral |
dc.description.sponsorship | The PACTABA project was funded Bristol-Myers Squibb. We thank all participants from the PACTABA study for their collaboration. AJ and SM are supported by the DoCTIS project funded by the European Union’s H2020 programme (Grant #848028). This work was supported by funds from the Vall d’Hebron Hospital Research Institute and from IMIDomics S.L. We thank Dr Ariel Jaitovich (Albany Medical Centre, USA) for providing additional clinical data on the late COVID-19 cohort. |
dc.language.iso | eng |
dc.publisher | Nature Research |
dc.relation.ispartofseries | Scientific Reports;11 |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | COVID-19 (Malaltia) - Tractament |
dc.subject | Medicaments immunosupressors - Ús terapèutic |
dc.subject | Artritis reumatoide - Tractament |
dc.subject.mesh | Coronavirus Infections |
dc.subject.mesh | Immunosuppressive Agents |
dc.subject.mesh | Arthritis, Rheumatoid |
dc.subject.mesh | /drug therapy |
dc.title | Targeting of the CD80/86 proinflammatory axis as a therapeutic strategy to prevent severe COVID-19 |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1038/s41598-021-90797-0 |
dc.subject.decs | infecciones por Coronavirus |
dc.subject.decs | inmunosupresores |
dc.subject.decs | artritis reumatoide |
dc.subject.decs | /farmacoterapia |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Julià A, Bonafonte-Pardàs I, Gómez A, López-Lasanta M, López-Corbeto M, Martínez-Mateu SH, Lladós J, Marsal S] Grup de Recerca en Reumatologia, Servei de Reumatologia, Vall d’Hebron Hospital Institut de Recerca (VHIR), Barcelona, Spain |
dc.identifier.pmid | 34075090 |
dc.identifier.wos | 000660845500005 |
dc.relation.projectid | info:eu-repo/grantAgreement/EC/H2020/848028 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |